Perturbed IFN-γ-jak-signal transducers and activators of transcription signaling in tuberous sclerosis mouse models:: Synergistic effects of rapamycin-IFN-γ treatment

被引:50
作者
El-Hashemite, N [1 ]
Zhang, HB [1 ]
Walker, V [1 ]
Hoffmeister, KM [1 ]
Kwiatkowski, DJ [1 ]
机构
[1] Harvard Univ, Sch Med, Dept Med, Hematol Div,Brigham & Womens Hosp, Boston, MA 02115 USA
关键词
D O I
10.1158/0008-5472.CAN-03-3609
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Tuberous sclerosis complex (TSC) is an autosomal dominant disorder characterized by widespread development of hamartomas, which is caused by mutations in either TSC1 or TSC2. We demonstrate a dramatic decrease of IFN-gamma expression in tumors and mouse embryo fibroblast cell lines that lack either Tsc1 or Tsc2, which is reversed by rapamycin (mammalian target of rapamycin inhibitor) therapy. Increased signal transducers and activators of transcription (STAT) 1 expression and phosphorylation at Ser 727 and increased pSTAT3 Tyr705 levels also are seen in Tsc1 null and Tsc2 null cells and in tumors. Treatment of Tsc1 or Tsc2 null cells with IFN-gamma induces apoptosis, in contrast to control cell lines, with reduction in pSTAT3 Tyr705 levels and major increases in pSTAT1 Tyr701, bax, and caspase-1 and -9 levels. A combination of IFN-gamma and rapamycin is markedly synergistic in induction of apoptosis in Tsc1 or Tsc2 null cells because pSTAT3 Tyr705 phosphorylation is abolished completely and the other effects of IFN-gamma are maintained or enhanced. Rapamycin-IFN-gamma has unique potential therapeutic benefit for management of TSC tumors.
引用
收藏
页码:3436 / 3443
页数:8
相关论文
共 32 条
  • [1] IFN-γ inhibits human airway smooth muscle cell proliferation by modulating the E2F-1/Rb pathway
    Amrani, Y
    Tliba, O
    Choubey, D
    Huang, CD
    Krymskaya, VP
    Eszterhas, A
    Lazaar, AL
    Panettieri, RA
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, 2003, 284 (06) : L1063 - L1071
  • [2] Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma
    Bromberg, JF
    Horvath, CM
    Wen, ZL
    Schreiber, RD
    Darnell, JE
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (15) : 7673 - 7678
  • [3] Molecular genetic advances in tuberous sclerosis
    Cheadle, JP
    Reeve, MP
    Sampson, JR
    Kwiatkowski, DJ
    [J]. HUMAN GENETICS, 2000, 107 (02) : 97 - 114
  • [4] Association between a high-expressing interferon-γ allele and a lower frequency of kidney angiomyolipomas in TSC2 patients
    Dabora, SL
    Roberts, P
    Nieto, A
    Perez, R
    Jozwiak, S
    Franz, D
    Bissler, J
    Thiele, EA
    Sims, K
    Kwiatkowski, DJ
    [J]. AMERICAN JOURNAL OF HUMAN GENETICS, 2002, 71 (04) : 750 - 758
  • [5] Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs
    Dabora, SL
    Jozwiak, S
    Franz, DN
    Roberts, PS
    Nieto, A
    Chung, J
    Choy, YS
    Reeve, MP
    Thiele, E
    Egelhoff, JC
    Kasprzyk-Obara, J
    Domanska-Pakiela, D
    Kwiatkowski, DJ
    [J]. AMERICAN JOURNAL OF HUMAN GENETICS, 2001, 68 (01) : 64 - 80
  • [6] Serine phosphorylation of STATs
    Decker, T
    Kovarik, P
    [J]. ONCOGENE, 2000, 19 (21) : 2628 - 2637
  • [7] Mutation in TSC2 and activation of mammalian target of rapamycin signalling pathway in renal angiomyolipoma
    El-Hashemite, N
    Zhang, HB
    Henske, EP
    Kwiatkowski, DJ
    [J]. LANCET, 2003, 361 (9366) : 1348 - 1349
  • [8] El-Hashemite N, 2003, CANCER RES, V63, P5173
  • [9] Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2
    Garami, A
    Zwartkruis, FJT
    Nobukuni, T
    Joaquin, M
    Roccio, M
    Stocker, H
    Kozma, SC
    Hafen, E
    Bos, JL
    Thomas, G
    [J]. MOLECULAR CELL, 2003, 11 (06) : 1457 - 1466
  • [10] Gomez MR., 1999, TUBEROUS SCLEROSIS C